Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865249 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2TAAR1AKR1B1KMT2AKDM4E | |
| SCHEMBL17055847 | 0.77 | KDM4E (0.53) | SMN1; SMN2TAAR1AKR1B1KMT2AKDM4E | |
| SCHEMBL3156120 | 0.77 | IDO1 (0.60) | TAAR1KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL4796828 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2TAAR1AKR1B1KMT2AKDM4E | |
| SCHEMBL3160629 | 0.76 | IDO1 (0.57) | TAAR1IDO1 | |
| SCHEMBL925766 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2TAAR1AKR1B1KMT2AKDM4E | |
| SCHEMBL18788868 | 0.74 | TSHR (0.62) | SMN1; SMN2AKR1B1KMT2AALDH1A1IDO1 | |
| SCHEMBL10457899 | 0.74 | TAAR1 (0.43) | SMN1; SMN2TAAR1AKR1B1KMT2AKDM4E | |
| SCHEMBL3162254 | 0.73 | IDO1 (0.34) | IDO1 | |
| SCHEMBL2091194 | 0.73 | SLC22A12 (0.36) | TAAR1ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | SMN1; SMN2 3564/4885TAAR1 70/4885AKR1B1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.